Lactulose a day keeps encephalopathy at bay

医学 乳果糖 海湾 重症监护医学 内科学 海洋学 地质学
作者
Elizabeth Klinken,Gerry C. MacQuillan
出处
期刊:Journal of Gastroenterology and Hepatology [Wiley]
卷期号:26 (6): 939-940 被引量:5
标识
DOI:10.1111/j.1440-1746.2011.06742.x
摘要

It has been said that “lactulose is a many splendored thing . . . with many other beneficial actions in its bag of tricks.”1 Is the routine use of lactulose as prophylaxis for hepatic encephalopathy following an acute variceal bleed another “trick” to be pulled out of the proverbial bag? The use of lactulose has long been applied in the setting of constipation. In 1966, lactulose was introduced in the treatment of hepatic encephalopathy by Bircher et al.2 Despite a relative lack of high-powered studies conclusively proving its beneficial effect over placebo,3 lactulose is still considered first-line management (along with the identification and correction of precipitating factors).4 The development of overt hepatic encephalopathy is itself a poor prognostic indicator.5, 6 Gastrointestinal bleeding, in particular, an acute variceal bleed, is a common precipitant of hepatic encephalopathy. The exact prognostic significance of hepatic encephalopathy in the context of an acute variceal bleed is unclear; however, following a first episode, the overall transplant-free survival at 1 year is only 42%.6 The pathogenesis of hepatic encephalopathy is complex and imprecisely defined. It is thought to revolve around elevated levels of ammonia, an inflammatory response, and subsequent astrocyte swelling leading to cerebral edema.5 The neuropsychiatric disorder that results is variable, and is by consensus clinically defined using the West Haven criteria developed by Conn et al. in 1977.7, 8 Ammonia is produced as a byproduct of the metabolism of nitrogen-containing compounds, abundant in the bacterial flora of the gastrointestinal tract. In the “normal” system, the liver removes systemic ammonia by converting it to the water soluble urea. In liver disease, however, this function is impaired (due to either hepatocellular failure or portosystemic shunting) and brain and muscle cells are increasingly involved, converting ammonia to glutamine.5, 9 The treatment of hepatic encephalopathy has thus focused around reducing the production and absorption of ammonia in the gut.5 Precipitants of hepatic encephalopathy are many. In the case of an acute gastrointestinal bleed, increased ammonia levels arise from the high protein load in the gut. The Baveno IV guidelines, and subsequent AASLD (American Association for the Study of Liver Diseases) practice guidelines, for the management of portal hypertension, outline key management issues immediately after an acute bleeding episode, including the recommendation for antibiotic prophylaxis for preventing bacterial infections/spontaneous bacterial peritonitis.10, 11 Furthermore, there is a recommendation that treatment with lactulose is indicated if hepatic encephalopathy eventuates.10, 11 However, while it would seem prudent to use lactulose as prophylaxis in a setting that is well known to precipitate the condition, this is not currently a guideline recommendation. Lactulose, a non-absorbable disaccharide, is not degraded in the upper gastrointestinal tract. Aside from its cathartic effect, lactulose reduces the synthesis and absorption of ammonia by driving the conversion of ammonia to the non-absorbable ammonium via a reduction in the colonic pH.5, 12 A Cochrane Review in 2004 of studies from 1969 to 2003 evaluated the beneficial effect of lactulose in hepatic encephalopathy, and concluded that the evidence was insufficiently sound to support its use. Furthermore, the authors recommended that it should not be utilized as a comparator in future trials.3 However, a study published in 2009 by Sharma et al. concluded that lactulose was in fact effective in the prevention of recurrent hepatic encephalopathy.13 In this open-label, randomized, controlled trial of 125 patients, randomly assigned to either lactulose or non-lactulose treatment, 20% (12/61) and 47% (30/64) developed overt hepatic encephalopathy, respectively (P = 0.001).13 In this study, non-response to lactulose was reported in patients with hyponatremia and very high venous ammonia levels.13 The study by Sharma et al. in this issue of the Journal of Gastroenterology and Hepatology14 examined the effectiveness of lactulose in the prevention of hepatic encephalopathy following an acute variceal bleed. The study involved the randomization of 70 patients to either 30 mL lactulose three to four times per day (ultimately to ensure 2–3 semiformed stools per day) or non-lactulose. Inclusion criteria included admission within 24 h of gastrointestinal bleed, no history of lactulose intake in the preceding 6 weeks, and no significant distracting comorbidity.14 The inclusion of patients with a prior history of encephalopathy rendered it as neither a primary nor secondary prophylaxis study. Bleeding was assessed and managed in accordance with Baveno IV guidelines, and hepatic encephalopathy was assessed as per West Haven criteria by two independent assessors. Approximately one-sixth of patients in each group received terlipressin instead of somatostatin as a vasoactive drug. Nineteen patients developed clinically-overt hepatic encephalopathy; 14% (5/35) in the lactulose group and 40% (14/35) in the non-lactulose group (P = 0.03), giving a relative risk reduction of 66%.14 The resultant increase in length of hospital stay of those who developed encephalopathy was also significant (11 ± 2.2 vs 7 ± 1.8 days, P = 0.001).14 Those in the control group were treated with lactulose therapy once hepatic encephalopathy did develop. Confounding precipitants of hepatic encephalopathy are difficult to separate, although there were no significant biochemical differences between the two groups. Alternative therapies for hepatic encephalopathy include antibiotics, such as neomycin, that reduce ammonia-producing bacteria. These have been used in the long-term treatment of hepatic encephalopathy.4 However, more recently, they have lost favor secondary to their side-effect profiles. Rifaximin is a semisynthetic rifamycin-based antibiotic with gut-specific action as a result of its poor solubility and absorption.15 The negligible plasma levels of rifaximin bode well for avoiding potential drug resistance.15 Solid evidence for the use of rifaximin in the treatment of hepatic encephalopathy is largely a consequence of the randomized, controlled trial conducted by Bass et al.16 In that study, rifaximin was compared to placebo in patients in remission from recurrent hepatic encephalopathy, with breakthrough episodes reported in 22% (31/140) of patients in the rifaximin group and 46% (73/159) in the placebo group (P < 0.001). Of interest, over 90% of patients in both groups concomitantly used lactulose (the common adverse effects of which are bloating, abdominal cramping, and diarrhea). In contrast, rifaximin has not been shown to have a significant side-effect profile,16 certainly when compared to other previously utilized antibiotics, although long-term data are not yet available. Some of the adverse effects of lactulose can be minimized with the use of lactitol (an analog of lactulose);17 however, this is not available worldwide. Overtreatment of lactulose can lead to the more serious side-effects of marked dehydration, hyponatremia, and worsening of hepatic encephalopathy.5 The dosing regime of rifaximin can be either fixed daily or cyclical,15 whereas lactulose does rely on some degree of patient adjustment to ensure approximately two to three semiformed stools daily. Costing considerations are not straightforward. While the direct cost of rifaximin compared to lactulose is marked, approximately $US1120 as opposed to $150 per month in the USA,15 the total annual costing of rifaximin has been reported to be less than lactulose when hospital admissions are taken into account.18 The role of rifaximin in the prevention or treatment of hepatic encephalopathy following an acute variceal bleed remains to be elucidated. Even if no further conclusive studies confirming the beneficial effect of lactulose occur, it is difficult to conceive of it being substituted as first-line therapy for hepatic encephalopathy. Its routine prophylactic use in the setting of an acute variceal bleed (post-initial stabilization and endoscopic control of bleeding) seems intuitive. Perhaps prophylactic lactulose therapy should be considered for incorporation into acute variceal bleed practice guidelines as the “standard of care.”
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xjh的应助被花样年华采纳,获得150
2秒前
2秒前
2秒前
gong完成签到,获得积分10
2秒前
巷阳完成签到,获得积分10
3秒前
丘比特的应助被RUI采纳,获得10
3秒前
赘婿的应助被王大橙子采纳,获得10
4秒前
威菡完成签到,获得积分10
4秒前
俊逸一手完成签到,获得积分10
4秒前
4秒前
华仔的应助被奋斗的凡采纳,获得10
4秒前
123发布了新的文献求助10
5秒前
5秒前
Sean发布了新的文献求助10
5秒前
Gloria2023发布了新的文献求助20
5秒前
li完成签到,获得积分10
5秒前
5秒前
传奇3的应助被1001采纳,获得10
6秒前
6秒前
涤宇发布了新的文献求助10
6秒前
7秒前
lydia完成签到,获得积分10
7秒前
cdercder的应助被何喝采纳,获得10
7秒前
坚强孤容发布了新的文献求助10
7秒前
xjh的应助被热情的远锋采纳,获得10
8秒前
爆米花的应助被gaofan采纳,获得10
8秒前
Joy发布了新的文献求助10
9秒前
9秒前
鸡你太美完成签到,获得积分10
9秒前
9秒前
lydia发布了新的文献求助10
10秒前
SciGPT的应助被向阳而开采纳,获得10
11秒前
zhikaiyici发布了新的文献求助30
11秒前
duanzou完成签到,获得积分10
11秒前
11秒前
奋斗的凡完成签到,获得积分10
11秒前
Mint完成签到 ,获得积分10
12秒前
民工搬砖发布了新的文献求助10
12秒前
12秒前
涤宇完成签到,获得积分10
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183204
求助须知:如何正确求助?哪些是违规求助? 9572434
关于积分的说明 21825655
捐赠科研通 7779988
什么是DOI,文献DOI怎么找? 3433852
关于科研通互助平台的介绍 2558060
邀请新用户注册赠送积分活动 2480148